Crinetics Pharmaceuticals Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings results on Monday, August, 9th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.09.
View Crinetics Pharmaceuticals' earnings history.

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRNX stock has increased by 34.2% and is now trading at $20.80.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12 month price targets for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $45.00. On average, they anticipate Crinetics Pharmaceuticals' share price to reach $37.00 in the next year. This suggests a possible upside of 77.9% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view top-rated stocks among Wall Street analysts.

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Crinetics Pharmaceuticals include ALX Oncology (ALXO), Cryoport (CYRX), PTC Therapeutics (PTCT), Insmed (INSM), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Zentalis Pharmaceuticals (ZNTL), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), ACADIA Pharmaceuticals (ACAD), Prestige Consumer Healthcare (PBH) and Lyell Immunopharma (LYEL).
View all of CRNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (13.62%), Perceptive Advisors LLC (10.28%), Perceptive Advisors LLC (10.28%), BlackRock Inc. (6.90%), Bain Capital Life Sciences Investors LLC (4.36%) and Vanguard Group Inc. (4.00%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals.

CRNX stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, Virtus ETF Advisers LLC, and Victory Capital Management Inc.. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals or view top insider-selling stocks.

CRNX stock was acquired by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, BlackRock Inc., Sphera Funds Management LTD., Vanguard Group Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, Ghost Tree Capital LLC, and FMR LLC. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Perceptive Advisors Llc, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals or or view top insider-buying stocks.

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRNX stock can currently be purchased for approximately $20.80.

Crinetics Pharmaceuticals has a market capitalization of $802.13 million and generates $70,000.00 in revenue each year. The company earns $-73,810,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

Crinetics Pharmaceuticals employs 93 workers across the globe.

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at (858) 450-6464 or via email at [email protected].